CERS
Cerus Corporation
NASDAQ · Healthcare · Medical - Devices · US
$2.59
+0.78%Aug 18, 2026, 14:34 UTC
Cerus reported Q2 2026 results showing product revenue growth of 10%, a 7% decrease in operating expenses, and adjusted EBITDA more than tripling year-over-year.
Source:Jul 30, 2026, 20:01 UTC
Cerus Corporation announced its financial results for the second quarter of 2026.
Jun 8, 2026, 12:30 UTC
Cerus Corporation closed a new debt facility of up to $110 million with MidCap Financial, consisting of a term loan and an asset-backed revolving loan.
Source:Jun 8, 2026, 00:00 UTC
Cerus Corporation entered into a Second Amended and Restated Credit, Security and Guaranty Agreement on June 5, 2026, establishing a secured term loan facility of up to $65.0 million, with $35.0 million drawn at closing to refinance existing debt and $30.0 million available subject to lender approval, plus a secured revolving facility with an initial $30.0 million commitment.
Jun 3, 2026, 00:00 UTC
Cerus Corp elected William M. Greenman and Ann Lucena as directors effective June 2, 2026.